<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00200850</url>
  </required_header>
  <id_info>
    <org_study_id>H-2005-0193</org_study_id>
    <secondary_id>R21AT002326-01A1</secondary_id>
    <nct_id>NCT00200850</nct_id>
  </id_info>
  <brief_title>Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy</brief_title>
  <official_title>Sublingual Immunotherapy in Dust Mite Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate sublingual immunotherapy (SLIT), a treatment involving antigens
      placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing
      substances. Specifically, this study will determine the effectiveness of SLIT at two
      different dosing regimens for patients with intermittent mild asthma caused by dust mites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a serious lung condition that is the leading cause of long-term illness in
      children. Many common household substances can trigger or worsen an asthma attack. It is
      important for people to reduce household allergens and learn effective treatments for
      specific types of asthma. Inhaled short-acting beta agonist such as albuterol is the standard
      treatment for mild, intermittent asthma. However, recent studies have shown that adding
      allergen-specific immunotherapy to your current asthma therapy can help to control asthma
      symptoms. This study will determine the safety and effectiveness of SLIT in two different
      dosing regimens in treating patients with house dust mite-induced allergic rhinitis/mild
      intermittent asthma.

      Participants will be randomly assigned to receive low dose SLIT, high dose SLIT, or placebo
      for at least 12 months. House dsut mite-induced allergy skin tests will be performed at study
      entry, at selected timepoints throughout the study, and at the end of the study. The tests
      will determine whether SLIT creates an immune tolerance state as well as whether SLIT acts
      via local or systemic immunological systems.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in nasal allergy/asthma symptom score over a 4-week period</measure>
    <time_frame>baseline and after 12-18 months treatment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose SLIT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose SLIT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hose Dust Mite SLIT</intervention_name>
    <description>low dose SLIT 143 AU/ml daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose SLIT</intervention_name>
    <description>House Dust Mite SLIT- 10,000 AU/ml daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo SLIT</intervention_name>
    <description>Placebo SLIT daily</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  House dust mite-induced allergic rhinitis/mild intermittent asthma

        Exclusion Criteria:

          -  Use of previous allergy immunotherapy for house dust mite asthma

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert K. Bush, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Medical School</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breathing</keyword>
  <keyword>Allergy</keyword>
  <keyword>Mites, House Dust</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

